1/51
Vocabulary practice flashcards covering clinical definitions, diagnostic thresholds, landmark trials, screening criteria, and therapeutic targets from the ADA Standards of Care and Cardiovascular Goals lecture.
Population Health
The health outcomes of a group of individuals, including the distribution of outcomes within the group, measured via mortality, morbidity, health status, functional status, disease burden (incidence and prevalence), and behavioral or metabolic factors.
General Population Diabetes Screening Guideline
Universal screening for prediabetes and type 2 diabetes recommended for all asymptomatic individuals starting at age 35, repeated at a minimum of 3-year intervals if results are normal.
Risk-Based Screening for Type 2 Diabetes
Screening performed at any age in asymptomatic adults with a BMI⋈≥25kg/m2 (≥23kg/m2 in Asian Americans) who have one or more additional risk factors, such as a first-degree relative with diabetes, high-risk ethnicity, physical inactivity, or history of cardiovascular disease.
Cystic Fibrosis-Related Diabetes (CFRD) Screening
Annual screening beginning at age 10 using an Oral Glucose Tolerance Test (OGTT). A1C is not recommended as a screening tool for CFRD. (Beginning 5 years after the diagnosis of
CFRD, annual monitoring for complications
of diabetes is recommended.)
Post-Transplantation Diabetes Mellitus (PTDM)
Hyperglycemia detected after organ transplantation screened via OGTT once the recipient is stable on an immunosuppressive regimen and free of acute infection.
Prediabetes Diagnostic Criteria
A biochemical classification defined by an A1C of 5.7–6.4% or a fasting plasma blood glucose of 100–125mg/dL.
Diabetes Prevention Program (DPP)
A landmark clinical trial showing that an intensive lifestyle intervention achieving 5–7% weight loss and 150minutes of weekly physical activity reduced the risk of developing type 2 diabetes by 58% in individuals with prediabetes.
Sleep Quality (in Diabetes Risk)
An individual's self-satisfaction with all aspects of the sleep experience; poor sleep quality is associated with a 40% increased risk of developing type 2 diabetes.
Evening Chronotype (Night Owls)
A circadian rhythm preference associated with 2.5 times higher odds of developing type 2 diabetes compared to morning chronotypes (early birds).
Metformin for Prediabetes Prevention
Preventive pharmacotherapy considered for high-risk individuals aged 25–59years with BMI≥35kg/m2, A1C≥6.0%, or a history of gestational diabetes mellitus (GDM).
GLP-1 Therapy in Prediabetes
Glucagon-like peptide 1-based therapy used for weight management in individuals with BMI≥25kg/m2, where each kilogram of weight loss produces a 16% risk reduction of progression to diabetes over 3.2years.
Estimated Average Glucose (eAG)
A calculated average blood glucose derived from the A1C level using the formula eAG=28.7×A1C−46.7, corresponding to roughly 29mg/dL for each 1% increment in A1C.
Fructosamine Test
A lab test measuring glucose bound to albumin reflecting glycemic control over the preceding 2–4weeks, useful during pregnancy, rapid treatment alterations, or conditions with altered red blood cell turnover where A1C is unreliable.
Time in Range (TIR)
The percentage of time an individual's glucose levels remain within the target window of 70–180mg/dL, with a standard clinical goal of >70% of readings for most non-pregnant adults.
Time Below Range (TBR)
Continuous glucose monitoring metric tracking hypoglycemia; clinical targets for non-frail adults are <4% of time below 70mg/dL and <1% of time below 54mg/dL.
Time Above Range (TAR)
Continuous glucose monitoring metric tracking hyperglycemia; standard targets are <25% of time above 180mg/dL and <5% of time above 250mg/dL.
Ambulatory Glucose Profile (AGP)
A standardized, single-page visual report that presents continuous glucose monitoring metrics including Time in Range, Glucose Management Indicator (GMI), average glucose, and glucose variability.
Glucose Variability Target (%CV)
A continuous glucose monitoring stability metric calculated as the percent coefficient of variation, with a standard target of ≤36%.
Diabetes Control and Complications Trial (DCCT)
A landmark 10-year study of over 1,400 participants with type 1 diabetes showing that intensive glycemic control (\text{A1C} < 7\%$) reduced eye disease by 76\%,kidneydiseaseby50\%,andnervediseaseby60\%$$.
United Kingdom Prospective Diabetes Study (UKPDS)
A landmark 20-year study of over 5,100 patients with type 2 diabetes establishing that each 1% decrease in A1C reduced microvascular complications by 35% and diabetes-related deaths by 25%.
Legacy Effect
The enduring long-term reduction in microvascular and macrovascular complications over 20 to 30 years resulting from early, intensive blood glucose control, even if A1C levels subsequently increase.
Cardiometabolic Risk: The 5 Hypers
Five clinical manifestations associated with insulin resistance syndrome: hyperinsulinemia, hyperglycemia, hyperlipidemia, hypertension, and hyper'waistline'emia (≥35inches in women, ≥40inches in men).
Cardiorenal Metabolic Disease
The interconnected clinical triad of atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), and chronic kidney disease (CKD) driven by shared metabolic risk factors in diabetes.
Albuminuria Diagnostic Threshold
A persistent urinary albumin-to-creatinine ratio (UACR) of ≥30mg/g, which dictates the selection of an ACE inhibitor or ARB as first-line blood pressure therapy in diabetes.
Dual Antihypertensive Initiation Threshold
A confirmed blood pressure reading of ≥150/90mmHg, requiring the immediate simultaneous initiation of two antihypertensive agents from complementary drug classes.
High-Intensity Statin Therapy
Statin therapy designed to lower LDL cholesterol by ≥50%, consisting of atorvastatin 40–80mg daily or rosuvastatin 20–40mg daily.
Moderate-Intensity Statin Therapy
Statin therapy that lowers LDL cholesterol by 30–49%, including atorvastatin 10–20mg, rosuvastatin 5–10mg, simvastatin 20–40mg, or pravastatin 40–80mg.
LDL Target: Secondary ASCVD Prevention
A target reduction in LDL cholesterol of ≥50% from baseline to achieve an absolute goal of <55mg/dL (<1.4mmol/L) in individuals with diabetes and established ASCVD.
LDL Target: Primary Prevention with Risk Factors
A recommended LDL cholesterol reduction of ≥50% from baseline to achieve a goal of <70mg/dL (<1.8mmol/L) for individuals aged 40–75years with diabetes and at least one cardiovascular risk factor.
Secondary Prevention Antiplatelet Strategy
The use of aspirin (75–162mg/day) or clopidogrel (75mg/day if aspirin-allergic) in individuals with diabetes and established ASCVD.
Dual Pathway Antithrombotic Therapy
Combination therapy with aspirin 81mg once daily plus rivaroxaban 2.5mg twice daily to prevent major adverse limb and cardiovascular events in patients with stable CAD/PAD and low bleeding risk.
Finerenone
A nonsteroidal mineralocorticoid receptor antagonist (MRA) indicated for patients with type 2 diabetes and chronic kidney disease to reduce the risk of hospitalization for heart failure.
4Ms Framework
An age-friendly health systems framework that focuses geriatric care on four core elements: What Matters Most, Medications, Mentation, and Mobility.
Glycemic Goal De-Intensification
Relaxing glycemic targets to an A1C<8.0%, TIR≥50%, and TBR≤1% for older adults with complex health, intermediate life expectancy, high treatment burden, or severe hypoglycemia risk.
Hyperglycemic Ketosis-Cannabis Hyperemesis Syndrome
A distinct presentation in adolescents with type 1 diabetes and ketosis characterized by normal or near-normal acid-base balance (pH≥7.4 and bicarbonate >15mmol/L) driven by recreational cannabis use.
Pneumococcal Conjugate Vaccine (PCV) Schedule
Immunization for adults aged 19–64years with diabetes using either a single dose of PCV20 or PCV15 followed by PPSV23 at least 1year later.
Zoster Vaccine (Shingrix)
A 2-dose recombinant shingles vaccine recommended for all adults with diabetes aged ≥50years.
Hepatitis B Vaccination Schedule
A 2-to-3 dose vaccination series recommended for all unvaccinated adults with diabetes aged ≤60years.
RSV Vaccine
A single-dose respiratory syncytial virus vaccine recommended for adults with diabetes aged ≥60years.
What is the preferred approach when providing diabetes education to
a child with type one diabetes on an insulin pump?
a. Individualize goals based on assessment
b. Encourage parents to collaborate to meet national standards
c. Highlight risk of complications when goals aren’t achieved
d. Gently remind them that insulin therapy improves outcomes.
Individualize goals based on assessment
According to ADA 2026 Standards, who should be screened for
prediabetes/ diabetes?
a. JR, has family history of diabetes, BMI 22, age 32
b. MS, age 37
c. LK, smokes, has HTN age 33
d. RA, Hispanic, low HDL, avg wt
b. MS, age 37
According to the Diabetes Prevention Program (DPP), losing 5-7 % of body
weight and accumulating 150 minutes activity a week can:
a. Help prevent type 1 diabetes
b. Lower risk of getting prediabetes
c. Decrease risk of getting diabetes
d. Prevent type 2 diabetes
Prevent type 2 diabetes
JL is 59 years old with type 1 diabetes. JL tells you they got their Herpes Zoster and pneumococcal vaccine. What other vaccines
are recommended for JL?
1. Influenza vaccine and Hepatitis B
2.Pneumonia and Human Papilloma Virus (HPV)
3. TDAP and Pneumonia
4.COVID and Human Papilloma Virus (HPV)
1. Influenza vaccine and Hepatitis B
LS is currently unemployed and without health insurance. LS takes Metformin 500mg BID and tells you they can’t afford strips to check their blood
glucose daily. What is the best response?
a. Inform provider that LS is non-adherent due to financial issues
b. Encourage LS to borrow strips from friends or trusted relatives
c. Set up a fund for uninsured for this purpose
d. Check LS’s blood glucose levels at each office visit
d. Check LS’s blood glucose levels at each office visit
JL is 78 and drinks a “few cocktails” every night. Lives with partner and takes
basal insulin at night and bolus insulin as needed. Checks BG a
few times a week. Most recent A1C was 5.5%. What is a safe
Time in Range Target (TIR) for JL? A. TIR of 80%, below
range less than 10% B. TIR 50%, below
range less than 1% C. Ask JL to determine their TIR target
D. Keep coefficient of variation less than 36%.
TIR 50%, below range less than 1%
According to the American Association of Clinical Endo (AACE), what is the
A1C goal?a. Less than 6.5 for all people with diabetes
b. Pre meal blood glucose less than 110
c. A1C less than 7%
d. A1C less than 6.5 for healthy individuals
d. A1C less than 6.5 for healthy individuals
Which study demonstrated that keeping A1C less than 7% reduces
complications for Type 1?
a. Diabetes Prevention Trial
b. Diabetes Control and Complications Trial
c. United Kingdom Prospective Diabetes Study
d. YOUTH Trial
b.Diabetes Control and Complications Trial
Which of the following BEST describes insulin resistance?
a. Lack of sufficient insulin receptors on fat and muscle cells.
b. Excess visceral adipose tissue.
c. A physiological condition where insulin becomes less effective at lowering blood glucose levels.
d. Upregulation of GLUT-4 transporters on cell surface
c. A physiological condition where insulin becomes less effective at lowering blood glucose levels.
WS has a history of a stroke, diabetes for 12 years and smokes
a pack a day. Which of the following actions would most
reduce risk of a future CV event?
a. Lose 5-7% of body weight
b. Stop smoking
c. Start aspirin therapy
d. Initiate a Mediterranean Diet
b. Stop smoking
78 year old, A1C 7.3, LDL 86, B/P 102/54 GFR 58, UACR
36mg/g. C/o of dizziness. Hx of stroke. Based on ADA guidelines, what
meds missing?Current Meds: Insulin – 16 units glargine at HS
Losartan 25 mg
Metoprolol 50mg
Glipizide 20mg in am
a. Metformin and ARB
b. Vitamin D and SGLT2
c. Bolus insulin and ACE
d. Statin and Aspirin
d. Statin and Aspirin (Secondary Cardiovascular Prevention: This patient has diabetes and a history of stroke, which classifies them as having established atherosclerotic cardiovascular disease (ASCVD). For these individuals, the American Diabetes Association (ADA) Standards of Care strongly recommend secondary prevention therapies. [1]
Missing Statin: A high-intensity statin is indicated for secondary prevention in patients with established ASCVD to mitigate further cardiovascular and cerebrovascular events, regardless of the baseline LDL level. This patient has an LDL of 86 mg/dL and is not currently on a lipid-lowering medication. [1]
Missing Aspirin: Antiplatelet therapy with low-dose aspirin is indicated as a secondary prevention strategy for patients with a documented history of ASCVD to reduce the risk of recurrent stroke or myocardial infarction)
Based on this case study,which first concern are you
going to address?
a. Monitoring salt intake.
b. Weight loss counseling.
c. Keeping conversation person centered.
d. Blood pressure monitoring.
d. Blood pressure monitoring.
RT, is a healthy 74-year-old who is on metformin 1000mg BID. He has had diabetes for 11 years. His latest A1C was 7.3% What is
best response? A. Good job, let’s get the A1C less than 7% B. Have you been snacking more than
usual? C. What do you think about your A1C level? D. Let’s add on another medication to get your A1C to target.
C. What do you think about your A1C level? (Patient-Centered Communication: Leading with an open-ended question is a core clinical technique used to assess the patient's own understanding, perception, and attitude toward their health data before jumping into adjustments or assumptions.
Individualized Glycemic Targets: According to the American Diabetes Association (ADA) guidelines for older adults, glycemic targets should be individualized based on overall health status. For a healthy 74-year-old with few co-morbidities, a reasonable and safe A1C target is usually < 7.5% (or < 7.0% if there is an exceptionally long life expectancy and low risk of hypoglycemia). Because RT's A1C is 7.3%, he is actually within a very acceptable clinical range for his age group)